Skip to main content
. Author manuscript; available in PMC: 2015 Oct 21.
Published in final edited form as: Clin Pharmacol Ther. 2008 May 28;85(2):155–163. doi: 10.1038/clpt.2008.95

Table 3. Clearance of docetaxel as a function of the observed genotypes.

Gene (allele) Reference genotype Heterozygote genotype Variant genotype P-valueb
Valuea N Valuea N Valuea N
SLCO1B3
 334T>G 32.1 1 27.0 (15.8–36.3) 25 23.2 (20.7–27.5) 65 0.58
 439A>G 23.3 (20.8–27.4) 90 29.7 1 N/A 0 0.41
 699G>A 40.1 2 27.0 (15.8–34.2) 25 22.2 (19.8–26.8) 63 0.22
 767G>C 22.7 (18.6–28.3) 60 26.8 (21.1–31.0) 25 16.0 4 0.17
 1559A>C 23.4 (20.8–27.5) 91 N/A 0 N/A 0 N/A
 1679T>C 23.2 (20.8–27.4) 89 28.5 1 63.4 1 0.21
CYP3A4
 −392A>G 22.9 (20.7–27.0) 82 37.0 (15.0–50.4) 9 N/A 0 0.05
CYP3A5
 6986A>G 34.2 1 33.6 (18.6–42.6) 12 22.9 (19.8–26.8) 78 0.06
ABCB1
 1236C>T 21.7 (15.3–29.6) 24 24.7 (18.8–28.5) 48 22.6 (16.4–31.0) 17 0.91
 2677G>T/Ac 23.2 (18.1–29.7) 25 25.2 (20.8–28.5) 50 20.7 (15.0–48.5) 15 0.88
 3435C>T 21.1 (14.5–29.6) 19 26.4 (18.8–28.9) 48 24.7 (18.6–28.4) 23 0.38
ABCC2
 −1019A>G 27.1 (18.8–29.7) 34 21.8 (18.6–28.5) 43 21.0 (14.5–27.0) 14 0.34
 −24C>T 24.7 (21.1–28.5) 61 21.7 (16.9–28.1) 26 20.3 4 0.69
 1249G>A 23.6 (18.6–27.4) 54 23.2 (17.3–29.2) 33 35.8 2 0.62
 IVS26 –34T>C 23.3 (20.8–27.4) 82 24.8 (9.70–34.2) 8 28.3 1 0.90
 3972C>T 24.0 (15.8–28.4) 38 21.8 (18.1–27.5) 41 27.6 (21.5–42.6) 12 0.42
 4544G>A 23.4 (20.8–27.5) 83 20.5 (9.70–73.9) 6 N/A 0 0.61

N, number of patients; N/A, not available.

a

Data represent median clearance of docetaxel in units of l/h with range in the parentheses.

b

P values were obtained from a two-tailed Mann–Whitney U-test (two-group comparisons) or a Kruskal–Wallis test (multiple-group comparisons).

c

In the heterozygote group, 49 patients had the GT genotype and 1 had the GA genotype; in the variant group, 12 patients had the TT genotype and 3 had the TA genotype.

HHS Vulnerability Disclosure